Stock CTKB CYTEK BIOSCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Cytek Biosciences, Inc.

Equities

CTKB

US23285D1090

Advanced Medical Equipment & Technology

Delayed Nasdaq
Other stock markets
 03:59:38 2024-05-23 pm EDT 		5-day change 1st Jan Change
5.92 USD -0.84% Intraday chart for Cytek Biosciences, Inc. -4.21% -35.09%
May. 20 Cytek Biosciences, Inc. Adds Ability to Detect Subcellular Particles to Its Cell Analysis Systems CI
May. 13 Piper Sandler Adjusts Price Target on Cytek Biosciences to $8.50 From $10, Maintains Overweight Rating MT

Valuation

Fiscal Period: December 2021 2022 2023 2024 2025 2026
Capitalization 1 2,182 1,377 1,236 783.7 - -
Enterprise Value (EV) 1 1,818 1,038 975.4 577.7 557.1 521.4
P/E ratio 326 x 511 x -101 x -142 x 90.5 x 56 x
Yield - - - - - -
Capitalization / Revenue 17.1 x 8.39 x 6.39 x 3.75 x 3.16 x 2.81 x
EV / Revenue 14.2 x 6.33 x 5.04 x 2.77 x 2.25 x 1.87 x
EV / EBITDA 104 x 49 x 71.2 x 33.5 x 16.8 x 13 x
EV / FCF - - - - - -
FCF Yield - - - - - -
Price to Book 5.37 x 3.25 x 3.03 x 1.89 x 1.75 x 1.55 x
Nbr of stocks (in thousands) 133,726 134,853 135,549 131,273 - -
Reference price 2 16.32 10.21 9.120 5.970 5.970 5.970
Announcement Date 2/23/22 2/28/23 2/28/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Net sales 1 - 128 164 193.4 208.9 247.7 279.1
EBITDA 1 - 17.52 21.17 13.7 17.23 33.08 40.21
EBIT 1 - 16.66 -1.804 -26.78 -18.04 -5.043 7.833
Operating Margin - 13.02% -1.1% -13.85% -8.64% -2.04% 2.81%
Earnings before Tax (EBT) 1 - 5.948 1.26 -14.64 -11.12 4.993 17.85
Net income 1 19.41 4.443 2.576 -11.33 -9.097 3.535 12.22
Net margin - 3.47% 1.57% -5.86% -4.36% 1.43% 4.38%
EPS 2 - 0.0500 0.0200 -0.0900 -0.0420 0.0660 0.1067
Free Cash Flow - - - - - - -
FCF margin - - - - - - -
FCF Conversion (EBITDA) - - - - - - -
FCF Conversion (Net income) - - - - - - -
Dividend per Share 2 - - - - - - -
Announcement Date 7/2/21 2/23/22 2/28/23 2/28/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 38.9 35.06 40.16 40.48 48.3 37.09 49.69 48 58.6 44.86 49.77 52.44 62.16 50.58 58.18
EBITDA 1 - - - - - - 1.542 3.72 10.96 -0.679 2.656 4.313 10.94 1.555 6.038
EBIT 1 5.238 -2.357 -0.891 1.36 0.084 -12.16 -9.127 1.159 0.932 -10.73 -5.822 -3.941 2.455 -7.839 -4.101
Operating Margin 13.47% -6.72% -2.22% 3.36% 0.17% -32.79% -18.37% 2.41% 1.59% -23.93% -11.7% -7.51% 3.95% -15.5% -7.05%
Earnings before Tax (EBT) 1 0.454 -3.303 -1.401 1.85 4.114 -9.04 -6.595 -4.185 5.18 -8.993 -4.683 -2.735 4.192 -6.228 -1.388
Net income 1 0.225 -2.021 -0.598 1.666 3.529 -6.807 -4.388 -6.456 6.322 -6.169 -3.782 -2.437 4.501 -6.31 -1.279
Net margin 0.58% -5.76% -1.49% 4.12% 7.31% -18.35% -8.83% -13.45% 10.79% -13.75% -7.6% -4.65% 7.24% -12.48% -2.2%
EPS 2 0.001700 -0.0200 - 0.0100 0.0300 -0.0500 -0.0300 -0.0500 0.0400 -0.0500 -0.0275 -0.0125 0.0350 -0.0400 -0.006670
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 2/23/22 5/11/22 8/10/22 11/9/22 2/28/23 5/9/23 8/8/23 11/7/23 2/28/24 5/8/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - -
Net Cash position 1 - 365 339 261 206 227 262
Leverage (Debt/EBITDA) - - - - - - -
Free Cash Flow - - - - - - -
ROE (net income / shareholders' equity) - 6% 5.02% 2.01% 5.17% 7.52% 11.5%
ROA (Net income/ Total Assets) - - - - - - -
Assets 1 - - - - - - -
Book Value Per Share 2 - 3.040 3.140 3.010 3.160 3.410 3.850
Cash Flow per Share - - - - - - -
Capex 1 - - - 4.65 5.6 5.6 -
Capex / Sales - - - 2.4% 2.68% 2.26% -
Announcement Date 7/2/21 2/23/22 2/28/23 2/28/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Cytek Biosciences, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
5.97 USD
Average target price
9.8 USD
Spread / Average Target
+64.15%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

1st Jan change Capi.
CYTEK BIOSCIENCES, INC. Stock Cytek Biosciences, Inc.
-35.09% 784M
THERMO FISHER SCIENTIFIC Stock Thermo Fisher Scientific
+10.21% 226B
DANAHER CORPORATION Stock Danaher Corporation
+12.94% 198B
INTUITIVE SURGICAL, INC. Stock Intuitive Surgical, Inc.
+18.08% 142B
BOSTON SCIENTIFIC CORPORATION Stock Boston Scientific Corporation
+28.69% 111B
SIEMENS HEALTHINEERS AG Stock Siemens Healthineers AG
+2.09% 65.26B
EDWARDS LIFESCIENCES CORPORATION Stock Edwards Lifesciences Corporation
+14.70% 54.36B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD. Stock Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
+6.68% 50.94B
AGILENT TECHNOLOGIES, INC. Stock Agilent Technologies, Inc.
+8.22% 44.8B
GE HEALTHCARE TECHNOLOGIES INC. Stock GE HealthCare Technologies Inc.
+2.55% 36.8B
Other Advanced Medical Equipment & Technology
  1. Stock Market
  2. Equities
  3. CTKB Stock
  4. Financials Cytek Biosciences, Inc.